Chi-An Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/799618/publications.pdf Version: 2024-02-01

		117625	138484
142	4,348	34	58
papers	citations	h-index	g-index
143	143	143	6238
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Interleukin-6 promotes cervical tumor growth by VECF-dependent angiogenesis via a STAT3 pathway. Oncogene, 2003, 22, 1517-1527.	5.9	463
2	IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer. Cancer Research, 2011, 71, 424-434.	0.9	184
3	The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene, 2001, 20, 5799-5809.	5.9	149
4	Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochemical Journal, 2012, 442, 293-302.	3.7	129
5	Serous ovarian carcinoma patients with high alphaâ€folate receptor had reducing survival and cytotoxic chemoâ€response. Molecular Oncology, 2012, 6, 360-369.	4.6	113
6	Interleukin-6 in Cervical Cancer: The Relationship with Vascular Endothelial Growth Factor. Gynecologic Oncology, 2001, 82, 49-56.	1.4	101
7	Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. Journal of Gynecologic Oncology, 2013, 24, 342.	2.2	99
8	Influence of Histologic Type and Age on Survival Rates for Invasive Cervical Carcinoma in Taiwan. Gynecologic Oncology, 1999, 73, 184-190.	1.4	97
9	Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma. , 1999, 85, 651-657.		95
10	Serum Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasms: Correlation with Patient Survival. Gynecologic Oncology, 1999, 74, 235-240.	1.4	89
11	Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis. Molecular Therapy, 2010, 18, 1233-1243.	8.2	85
12	Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstetrics and Gynecology, 2000, 96, 721-726.	2.4	83
13	Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-ÂB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis, 2004, 26, 45-52.	2.8	80
14	A Novel Peptide Specifically Binding to Interleukin-6 Receptor (gp80) Inhibits Angiogenesis and Tumor Growth. Cancer Research, 2005, 65, 4827-4835.	0.9	79
15	Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up. Gynecologic Oncology, 2006, 101, 423-428.	1.4	79
16	Overexpression of Placenta Growth Factor Contributes to the Pathogenesis of Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 505-511.	5.6	76
17	Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology, 2009, 256, 83-91.	4.2	74
18	The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecologic Oncology, 2013, 128, 239-244.	1.4	68

#	Article	IF	CITATIONS
19	BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes. , 2019, 7, 313.		67
20	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB. Oncogene, 2005, 24, 390-398.	5.9	61
21	Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochemical Journal, 2009, 424, 449-458.	3.7	61
22	The genotypes and prognostic significance of human papillomaviruses in cervical cancer. International Journal of Cancer, 1994, 57, 181-184.	5.1	47
23	Pregnancy with Primary Tubal Placental Site Trophoblastic Tumor— A Case Report and Literature Review. Gynecologic Oncology, 1999, 73, 322-325.	1.4	47
24	Fusion Protein Vaccine by Domains of Bacterial Exotoxin Linked with a Tumor Antigen Generates Potent Immunologic Responses and Antitumor Effects. Cancer Research, 2005, 65, 9089-9098.	0.9	47
25	Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated wholeâ€body PET/MR: Correlation with pathological prognostic factors. Journal of Magnetic Resonance Imaging, 2015, 42, 1723-1732.	3.4	45
26	Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. Cancers, 2019, 11, 1400.	3.7	45
27	Vascular patterns of gestational trophoblastic tumors by color doppler ultrasound. Cancer, 1994, 74, 2361-2365.	4.1	44
28	Clinical significance of intratumoral blood flow in cervical carcinoma assessed by color doppler ultrasound. Cancer, 1995, 75, 2518-2522.	4.1	43
29	The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. Journal of Psychosomatic Obstetrics and Gynaecology, 2010, 31, 16-23.	2.1	43
30	Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan. PLoS ONE, 2012, 7, e51372.	2.5	43
31	Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Research, 2006, 26, 4721-8.	1.1	41
32	Rapid detection of ?-globin gene (HBB) mutations coupling heteroduplex and primer-extension analysis by DHPLC. Human Mutation, 2003, 22, 326-336.	2.5	39
33	Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation. Cancer Letters, 2015, 359, 117-126.	7.2	39
34	Vascular endothelial growth factor in cervical carcinoma. Obstetrics and Gynecology, 1999, 93, 761-765.	2.4	38
35	Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstetrics and Gynecology, 2000, 96, 615-621.	2.4	38
36	Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. Journal of Gynecologic Oncology, 2015, 26, 46.	2.2	38

#	Article	IF	CITATIONS
37	Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment. Molecular Therapy, 2018, 26, 404-419.	8.2	33
38	Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget, 2015, 6, 39740-39755.	1.8	33
39	Cytosol Vascular Endothelial Growth Factor in Endometrial Carcinoma: Correlation with Disease-Free Survival. Gynecologic Oncology, 2001, 80, 207-212.	1.4	32
40	Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Modern Pathology, 2015, 28, 303-311.	5.5	31
41	The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer. Annals of Surgical Oncology, 2015, 22, 1556-1565.	1.5	31
42	Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Letters, 2018, 425, 152-163.	7.2	31
43	DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecologic Oncology, 2007, 107, 404-412.	1.4	30
44	Clinical application of intratumoral blood flow study in patients with endometrial carcinoma. , 1998, 82, 1881-1886.		29
45	Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine, 2005, 23, 3864-3874.	3.8	28
46	Epidemiologic correlates of cervical human papillomavirus prevalence in women with abnormal Pap smear tests: A Taiwan cooperative oncology group (TCOG) study. Journal of Medical Virology, 2005, 77, 273-281.	5.0	26
47	Brain metastasis as a late manifestation of ovarian carcinoma. European Journal of Cancer Care, 2011, 20, 44-49.	1.5	26
48	Histone Deacetylase 6 Regulates Estrogen Receptor α in Uterine Leiomyoma. Reproductive Sciences, 2011, 18, 755-762.	2.5	26
49	Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses. PLoS ONE, 2012, 7, e47190.	2.5	25
50	Preoperative Ultrasound Study in Predicting Lymph Node Metastasis for Endometrial Cancer Patients. Gynecologic Oncology, 1998, 71, 424-427.	1.4	24
51	Endometrial stromal sarcoma of twenty cases. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 551-555.	2.8	23
52	Quantification of Relative Gene Dosage by Single-Base Extension and High-Performance Liquid Chromatography:Â Application to theSMN1/SMN2 Gene. Analytical Chemistry, 2005, 77, 6960-6968.	6.5	23
53	IL-6-Encoding Tumor Antigen Generates Potent Cancer Immunotherapy Through Antigen Processing and Anti-apoptotic Pathways. Molecular Therapy, 2007, 15, 1890-1897.	8.2	23
54	Arsenic Trioxide Inhibits CXCR4-Mediated Metastasis by Interfering miR-520h/PP2A/NF-κB Signaling in Cervical Cancer. Annals of Surgical Oncology, 2014, 21, 687-695.	1.5	23

#	Article	IF	CITATIONS
55	Chimeric DNA Vaccine Reverses Morphine-Induced Immunosuppression and Tumorigenesis. Molecular Therapy, 2006, 13, 203-210.	8.2	22
56	Concurrent Endometrial Carcinoma in Patients with a Curettage Diagnosis of Endometrial Hyperplasia. Journal of the Formosan Medical Association, 2009, 108, 502-507.	1.7	21
57	Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Frontiers in Pharmacology, 2019, 10, 426.	3.5	21
58	Correlation of Uterine Hemodynamics With Chemotherapy Response in Gestational Trophoblastic Tumors. Obstetrics and Gynecology, 1994, 83, 1021-1025.	2.4	20
59	Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer, 2007, 110, 420-431.	4.1	20
60	Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecologic Oncology, 2013, 131, 63-68.	1.4	20
61	Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. Endocrine-Related Cancer, 2013, 20, 213-227.	3.1	19
62	Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. Cancers, 2019, 11, 270.	3.7	19
63	Infrequent mutation in tumor suppressor gene p53 in gestational trophoblastic neoplasia. Carcinogenesis, 1994, 15, 2221-2223.	2.8	18
64	Coexistence of human cytomegalovirus and human papillomavirus type 16 correlates with lymph node metastasis in cervical cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 629-632.	2.5	18
65	Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecologic Oncology, 2009, 112, 35-39.	1.4	18
66	A Prospective Study of Gynecological Cancer Risk in Relation to Adiposity Factors: Cumulative Incidence and Association with Plasma Adipokine Levels. PLoS ONE, 2014, 9, e104630.	2.5	18
67	Large cell neuroendocrine carcinoma of the endometrium: A case report and literature review. Taiwanese Journal of Obstetrics and Gynecology, 2018, 57, 144-149.	1.3	18
68	Torsion of pedunculated subserous uterine leiomyoma: A rare complication of a common disease. Taiwanese Journal of Obstetrics and Gynecology, 2018, 57, 300-303.	1.3	18
69	Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Modern Pathology, 2006, 19, 1570-1577.	5.5	17
70	Antigen-Specific CD8+ T Lymphocytes Generated from a DNA Vaccine Control Tumors Through the Fas–FasL Pathway. Molecular Therapy, 2005, 12, 960-968.	8.2	16
71	Submucous Myoma Induces Uterine Inversion. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 159-161.	1.3	15
72	Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. European Journal of Immunology, 2004, 34, 1892-1900.	2.9	14

#	Article	IF	CITATIONS
73	Post-coital vaginal douching is risky for non-regression of low-grade squamous intraepithelial lesion of the cervix. Gynecologic Oncology, 2011, 120, 449-453.	1.4	14
74	Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1158-1166.	2.8	14
75	Validating a rapid, real-time, PCR-based direct mutation detection assay for preimplantation genetic diagnosis. Gene, 2014, 548, 299-305.	2.2	14
76	CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. Epigenomics, 2018, 10, 1397-1413.	2.1	14
77	CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells. Endocrine-Related Cancer, 2019, 26, 73-88.	3.1	14
78	Clear Cell Carcinoma of the Abdominal Wall as a Rare Complication of General Obstetric and Gynecologic Surgeries: 15 Years of Experience at a Large Academic Institution. International Journal of Environmental Research and Public Health, 2019, 16, 552.	2.6	14
79	Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology, 2005, 115, 136-149.	4.4	13
80	Identification of deletion and duplication genotypes of the <i>PMP22</i> gene using PCRâ€RFLP, competitive multiplex PCR, and multiplex ligationâ€dependent probe amplification: A comparison. Electrophoresis, 2008, 29, 618-625.	2.4	13
81	Urokinase-type Plasminogen Activator Resulting from Endometrial Carcinogenesis Enhances Tumor Invasion and Correlates with Poor Outcome of Endometrial Carcinoma Patients. Scientific Reports, 2015, 5, 10680.	3.3	13
82	Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 442-448.	1.3	13
83	Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Cancer Letters, 2019, 444, 20-34.	7.2	13
84	Ruptured Pseudoaneurysm of the External Iliac Artery in an Advanced Cervical Cancer Patient Treated by Endovascular Covered Stent Placement. Journal of the Formosan Medical Association, 2008, 107, 348-351.	1.7	12
85	Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects. Clinical Science, 2012, 123, 347-360.	4.3	12
86	Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Frontiers in Pharmacology, 2017, 8, 800.	3.5	12
87	Factors predicting parametrial invasion in patients with early-stage cervical carcinomas. PLoS ONE, 2018, 13, e0204950.	2.5	12
88	Radical hysterectomy alone or combined with neoadjuvant chemotherapy in the treatment of early stage bulky cervical carcinoma. Journal of the Formosan Medical Association, 2002, 101, 195-202.	1.7	12
89	Recent advances and problems in primary therapy for cervical cancer in Taiwan. Journal of the Formosan Medical Association, 2004, 103, 511-8.	1.7	12
90	Primary retroperitoneal teratoma. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 707-708.	2.8	11

#	Article	IF	CITATIONS
91	Rapid detection of FGFR3 gene mutation in achondroplasia by DHPLC system-coupling heteroduplex and fluorescence-enhanced primer-extension analysis. Journal of Human Genetics, 2004, 49, 399-403.	2.3	11
92	Comparison of the mismatch-specific endonuclease method and denaturing high-performance liquid chromatography for the identification of HBB gene mutations. BMC Biotechnology, 2008, 8, 62.	3.3	11
93	The correlations of sexual activity, sleep problems, emotional distress, attachment styles with quality of life: comparison between gynaecological cancer survivors and noncancer women. Journal of Clinical Nursing, 2014, 23, 985-994.	3.0	11
94	IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients. Endocrine-Related Cancer, 2015, 22, 703-711.	3.1	11
95	mTOR Inhibitors Can Enhance the Anti-Tumor Effects of DNA Vaccines through Modulating Dendritic Cell Function in the Tumor Microenvironment. Cancers, 2019, 11, 617.	3.7	11
96	The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin. Gynecologic Oncology, 1992, 47, 28-33.	1.4	10
97	Comparison between 'in vivo' and 'in vitro' methods for evaluating tumor angiogenesis using cervical carcinoma as a model. Angiogenesis, 1999, 3, 295-304.	7.2	10
98	Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 591-597.	2.8	10
99	Quality of life of patients with ovarian cancer in Taiwan: validation and application of the Taiwan Chinese version of the EORTC QLQâ€OV28. Psycho-Oncology, 2010, 19, 782-785.	2.3	10
100	High-risk human papillomavirus, other than type 16/18, in predominantly older Taiwanese women with high-grade cervical preinvasive lesions. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 222-226.	1.3	10
101	Systemic Lymphadenopathy as the Primary Symptom of Serous Surface Papillary Carcinoma of the Ovary. Gynecologic Oncology, 1995, 58, 251-254.	1.4	9
102	Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system. Archives of Gynecology and Obstetrics, 2010, 281, 683-695.	1.7	9
103	Clinical features and outcomes of neck lymphatic metastasis in ovarian epithelial carcinoma. World Journal of Surgical Oncology, 2013, 11, 255.	1.9	9
104	Radical trachelectomy for early stage cervical cancer: A case series and literature review. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 143-146.	1.3	9
105	Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center. International Journal of Environmental Research and Public Health, 2019, 16, 2561.	2.6	9
106	<scp>PET</scp> / <scp>MRI</scp> in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival. Journal of Magnetic Resonance Imaging, 2021, 53, 305-318.	3.4	9
107	A rapid and reliable detection system for the analysis of PMP22 gene dosage by MP/DHPLC assay. Journal of Human Cenetics, 2006, 51, 227-235.	2.3	8
108	Clinical Significance of Cytologic Atypical Squamous Cells of Undetermined Significance. Obstetrics and Gynecology, 2009, 113, 888-894.	2.4	8

#	Article	IF	CITATIONS
109	Impact of various treatment modalities on the outcome of stage IB1–IIA cervical adenocarcinoma. International Journal of Gynecology and Obstetrics, 2011, 112, 135-139.	2.3	8
110	Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: A Taiwanese Gynecologic Oncology Group study. European Journal of Cancer, 2014, 50, 3161-3167.	2.8	8
111	Long-term outcomes of surgical treatment for intravascular leiomyomatosis. Journal of the Formosan Medical Association, 2018, 117, 964-972.	1.7	8
112	Clinical management and risk reduction in women with low-grade squamous intraepithelial lesion cytology: A population-based cohort study. PLoS ONE, 2017, 12, e0188203.	2.5	8
113	Superficial angiomyxoma on the vulva of an adolescent. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 104-106.	1.3	7
114	Simultaneous occurrence of hepatic focal nodular hyperplasia and uterine endometrial stromal nodule in a patient having treated breast infiltrating ductal carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 585-586.	2.8	6
115	Malignant struma ovarii complicated by Trousseau's syndrome and repeated episodes of cerebral ischemic strokes: A case report. Gynecologic Oncology Case Reports, 2012, 2, 35-38.	0.9	6
116	Screening Frequency and Atypical Cells and the Prediction of Cervical Cancer Risk. Obstetrics and Gynecology, 2014, 123, 1003-1011.	2.4	6
117	Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer. Journal of Cancer Research and Clinical Oncology, 1994, 120, 678-682.	2.5	5
118	Factors influencing tumor cell kinetics in cervical cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 504-508.	2.5	5
119	Clear Cell Adenocarcinoma of the Uterine Cervix. Taiwanese Journal of Obstetrics and Gynecology, 2007, 46, 453-455.	1.3	5
120	New primers for methylation-specific polymerase chain reaction enhance specificity of detecting STAT1 methylation. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 43-49.	1.3	5
121	Establishment of a New Ovarian Cancer Cell Line CA5171. Reproductive Sciences, 2015, 22, 725-734.	2.5	5
122	Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 591-597.	2.8	5
123	Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. American Journal of Translational Research (discontinued), 2015, 7, 139-52.	0.0	5
124	Anti-CD40 antibody and toll-like receptor 3 ligand restore dendritic cell-mediated anti-tumor immunity suppressed by morphine. American Journal of Cancer Research, 2016, 6, 157-72.	1.4	5
125	Successful treatment of a combined interstitial and intrauterine pregnancy after tubal embryo transfer (TET). Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 752-755.	2.8	4
126	Overexpression of Her-2/ <i>neu</i> in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-κB: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis. Journal of Biomedical Science, 2004, 11, 249-259.	7.0	4

#	Article	IF	CITATIONS
127	Cervical Abscess with Vaginal Fistula After Extraperitoneal Cesarean Section. Journal of the Formosan Medical Association, 2007, 106, 1048-1051.	1.7	4
128	Fusion Protein Vaccines Targeting Two Tumor Antigens Generate Synergistic Anti-Tumor Effects. PLoS ONE, 2013, 8, e71216.	2.5	4
129	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. Biomedicines, 2021, 9, 1384.	3.2	4
130	Cell kinetics and radiosensitivity of cervical squamous cell carcinoma. Cancer Letters, 1994, 82, 135-140.	7.2	3
131	Solitary primary peritoneal carcinoma arising from the omentum. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 256-259.	1.3	3
132	Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study. Journal of Gynecologic Oncology, 2018, 29, e55.	2.2	3
133	Primary Ewing Family of Tumor Arising in the Ovary: A Case Report. International Journal of Gynecological Pathology, 2019, 38, 470-473.	1.4	3
134	Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A populationâ€based analysis. Cancer Medicine, 2021, 10, 6845-6854.	2.8	3
135	Vascular Endothelial Growth Factor and Prognosis of Cervical Carcinoma. Obstetrics and Gynecology, 2000, 96, 721-726.	2.4	2
136	Septic Shock after Intracervical Laminaria Insertion. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 76-78.	1.3	2
137	Leiomyomatosis with Extension to the Left Gluteal Muscle, Inferior Vena Cava, and Right Atrium. American Journal of Roentgenology, 2006, 187, W546-W547.	2.2	2
138	Clinical application of intratumoral blood flow study in patients with endometrial carcinoma. Cancer, 1998, 82, 1881-1886.	4.1	2
139	Vascular Endothelial Growth Factor in Cervical Carcinoma. Obstetrics and Gynecology, 1999, 93, 761-765.	2.4	1
140	Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer. Cancers, 2021, 13, 1386.	3.7	1
141	In vivo wireless biodiagnosis system for long-term bioactivity monitoring network. , 2004, 5394, 288.		0
142	Subcutaneous mass as the primary manifestation of gestational choriocarcinoma: A case report. Gynecologic Oncology Case Reports, 2012, 2, 11-13.	0.9	0